Experience
Alto Neuroscience Announces $147.9 Million IPO
February 6, 2024
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.
Related contacts
Related Practices & Industries
Cooley Secures Win for Sequenom Board in Securities Class Action
September 12, 2023
Cooley represented the former board of directors of Sequenom, a molecular diagnostics company, in a nearly seven-year-long securities class action brought by the company’s former investors.
Related contacts
Related Practices & Industries
Travere Sells Bile Acid Product Portfolio to Mirum
July 18, 2023
Cooley advised Travere Therapeutics, a biopharmaceutical company, on its definitive agreement to sell its bile acid product portfolio to Mirum Pharmaceuticals.
Related contacts
Related Practices & Industries
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Related contacts
Related Practices & Industries
Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion
December 20, 2022
A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.
Related contacts
Related Practices & Industries
Related news and events
Rankings & accolades
Legal 500: Key Lawyer – Securities Litigation: Defense (2021)
The Recorder: Top 100 Litigation Lawyers (2015)
Memberships & affiliations
American Bar Association
San Diego County Bar Association